Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
BT-549 | Cediranib | VEGFR/cKIT | RTK | 3.6412 | -0.1347 | 0.1497 | 0.0414 | 1.3011 | 8.4712 | 0.98092 |
PDXHCI002 | Doxorubicin | Chemo | Chemotherapy | 0.0040539 | -0.6545 | 0.9685 | 0.2951 | 0.9297 | 0.0087544 | 0.98094 |
HME1 | Cediranib | VEGFR/cKIT | RTK | 7.6446 | 0.0275 | 0.0214 | 0.0244 | 4.8856 | 8.7954 | 0.98095 |
HCC1954 | Bleomycin | Radiation | Misc | 0.043847 | -0.0884 | 0.6166 | 0.2476 | 0.7506 | 0.05535 | 0.98102 |
SUM159PT | Dasatinib | BCR/ABL | MAPK/nRTK | Inf | 0.5642 | 0.1850 | 0.0047 | 1.3689 | 0.14044 | 0.98104 |
SK-BR-3 | Alpelisib | PI3Ka | PI3K/mTOR | 0.48468 | -0.1428 | 0.3788 | 0.0660 | 0.4911 | 2.8836 | 0.98115 |
MDA-MB-453 | Neratinib | EGFR/HER2 | RTK | 0.036055 | -0.3216 | 0.5532 | 0.1255 | 0.4562 | 0.2347 | 0.98118 |
MDA-MB-468 | Cabozantinib | VEGFR2/MET | RTK | 8.9681 | 0.4233 | 0.0441 | 0.0115 | 1.7711 | 16.6732 | 0.9812 |
T47D | Bleomycin | Radiation | Misc | 0.19877 | -0.0840 | 0.4615 | 0.0190 | 0.9701 | 0.24632 | 0.9812 |
T47D | Cisplatin | Chemo | Chemotherapy | 1.5698 | 0.1019 | 0.2147 | 0.0055 | 1.3290 | 1.5705 | 0.98121 |
HCC1954 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0096629 | -0.3280 | 0.5536 | 0.1704 | 0.7380 | 0.018218 | 0.98125 |
MDA-MB-453 | Doxorubicin | Chemo | Chemotherapy | 0.0058313 | -0.3476 | 0.7915 | 0.1805 | 1.7510 | 0.0071438 | 0.98132 |
T47D | PF-4708671 | p70S6K | PI3K/mTOR | 3.7629 | 0.3659 | 0.1275 | 0.0024 | 1.0704 | 1.8083 | 0.98136 |
Hs 578T | Ipatasertib | AKT | PI3K/mTOR | 4.5924 | 0.4423 | 0.2458 | 0.0093 | 0.5006 | 0.34659 | 0.98155 |
HCC1428 | ABT-737 | Bcl2/XL | Misc | 4.0616 | 0.2431 | 0.1194 | 0.0716 | 1.0222 | 5.0858 | 0.98165 |
Hs 578T | Ceritinib | ALK | RTK | 0.96543 | -0.4356 | 0.3052 | 0.1254 | 0.8330 | 3.6097 | 0.98175 |
MDA-MB-468 | Olaparib | PARP | Misc | 7.9202 | 0.3408 | 0.0576 | 0.0179 | 1.6505 | 15.4105 | 0.98176 |
HCC1428 | Cediranib | VEGFR/cKIT | RTK | 3.1657 | -0.5502 | 0.1943 | 0.0619 | 1.9637 | 5.5392 | 0.98192 |
Hs 578T | Palbociclib | CDK4/6 | Cell cycle | 0.15611 | 0.3049 | 0.3195 | 0.0363 | 0.7223 | 0.037735 | 0.98196 |
SUM149PT | Taselisib | PI3Ka, g, d | PI3K/mTOR | 2.4708 | -0.2343 | 0.2099 | 0.0774 | 1.0520 | 7.0204 | 0.98198 |
SK-BR-3 | Topotecan | Topo I | Chemotherapy | 0.016549 | -0.2711 | 0.7941 | 0.1919 | 1.9350 | 0.01923 | 0.98214 |
BT-20 | Ipatasertib | AKT | PI3K/mTOR | 0.64483 | 0.1015 | 0.3111 | 0.0476 | 0.7459 | 0.59909 | 0.98219 |
HCC1419 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0091784 | -0.4046 | 0.8523 | 0.0945 | 0.5809 | 0.022714 | 0.98223 |
BT-549 | Doxorubicin | Chemo | Chemotherapy | 0.006482 | -0.3312 | 0.7603 | 0.1972 | 1.5744 | 0.0079126 | 0.9824 |
MDA-MB-436 | Olaparib | PARP | Misc | 1.536 | 0.2383 | 0.3050 | 0.0296 | 0.3132 | 51.2767 | 0.98251 |